Neuroferritinopathy

Neuroferritinopathy, also known as adult-onset basal ganglia disease or hereditary ferritinopathy, is a rare neurodegenerative disorder caused by mutations in the FTL gene, which encodes the ferritin light chain. It belongs to the group of neurodegeneration with brain iron accumulation (NBIA) disorders. The disease is characterized by the abnormal accumulation of iron and ferritin in the brain, particularly in the basal ganglia, as well as in other organs. This progressive iron deposition leads to neuronal damage and a range of movement and cognitive problems. The condition primarily affects the central nervous system and typically presents in adulthood, usually between the ages of 40 and 60. Key clinical features include progressive movement abnormalities such as chorea (involuntary jerky movements), dystonia (sustained abnormal postures), parkinsonism (tremor, rigidity, and slowness of movement), and cerebellar signs including ataxia. Cognitive decline and behavioral changes may develop as the disease progresses. Some patients also develop dysarthria (difficulty speaking) and dysphagia (difficulty swallowing). Brain MRI characteristically shows iron deposition in the basal ganglia, with cystic cavitation of the putamen and globus pallidus being a distinctive radiological hallmark. Serum ferritin levels may be low or low-normal, which can be a helpful diagnostic clue. There is currently no cure or disease-modifying treatment for neuroferritinopathy. Management is symptomatic and supportive, focusing on alleviating movement disorder symptoms. Some patients may benefit from medications used for dystonia or chorea, though responses are often limited and may diminish over time. Iron chelation therapy has been explored but has not demonstrated clear clinical benefit. The disease is slowly progressive, and patients may eventually require assistance with daily activities. Genetic counseling is recommended for affected families given the hereditary nature of the condition.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Neuroferritinopathy